1-20 of 126
Debu Tripathy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers

Juliana Navarro-Yepes, Nicole M. Kettner, Xiayu Rao, Cassandra Santaella Bishop, Tuyen N. Bui, Hannah F. Wingate, Akshara Singareeka Raghavendra, Yan Wang, Jing Wang, Aysegul A. Sahin, Funda Meric-Bernstam, Kelly K. Hunt, Senthil Damodaran, Debu Tripathy, Khandan Keyomarsi
Journal: Cancer Research
Cancer Res OF1–OF20.
https://doi.org/10.1158/0008-5472.CAN-23-0705
Published: 11 September 2023
View article titled, Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Open the PDF for Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract LB042: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd)in tamoxifen-resistant ER+ breast cancer cells by inducing DNA damage and apoptosis

Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Young J. Gi, Thanasis Poullikkas, Pang-Dian Fan, Kumiko Koyama, Debu Tripathy, Naoto T. Ueno
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): LB042.
https://doi.org/10.1158/1538-7445.AM2023-LB042
Published: 14 April 2023
View article titled, Abstract LB042: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd)in tamoxifen-resistant ER<sup>+</sup> breast cancer cells by inducing DNA damage and apoptosis
Journal Articles

Abstract 1395: Genomic and transcriptomic analyses identify distinct features of triple-negative inflammatory breast cancer

Xiaoping Wang, Li Zhao, Takashi Semba, Xingzhi Song, Mark Knafl, Savitri Krishnamurthy, Shan Shao, Larry W. Coffer, II, Angela Alexander, Anita Wood, Swetha Bopparaju, Wendy A. Woodward, Randy Chu, Jianhua Zhang, Scott Woodman, Andrew Futreal, Clinton Yam, Debu Tripathy, Naoto T. Ueno
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1395.
https://doi.org/10.1158/1538-7445.AM2023-1395
Published: 04 April 2023
View article titled, Abstract 1395: Genomic and transcriptomic analyses identify distinct features of triple-negative inflammatory breast cancer
Journal Articles

Abstract 3635: TBK1 inhibition potentiates the efficacy of AXL-targeted therapy by modulating tumor microenvironment in aggressive breast cancers

Lan Phi, Takashi Semba, Ngu V. Trinh, Fang Zou, Jason M. Foulks, Steven L. Warner, Savitri Krishnamurthy, James P. Long, James M. Reuben, Debu Tripathy, Naoto T. Ueno, Xiaoping Wang
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3635.
https://doi.org/10.1158/1538-7445.AM2023-3635
Published: 04 April 2023
View article titled, Abstract 3635: TBK1 inhibition potentiates the efficacy of AXL-targeted therapy by modulating tumor microenvironment in aggressive breast cancers
Journal Articles

Abstract P4-08-15: Identification of target kinases whose inhibition enhances antitumor efficacy of sacituzumab-govitecan in metastatic HER2-negative breast cancer

Nakyung Oh, Jon A. Fuson, Huey Liu, Debu Tripathy, Naoto T. Ueno, Jangsoon Lee
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P4-08-15.
https://doi.org/10.1158/1538-7445.SABCS22-P4-08-15
Published: 01 March 2023
View article titled, Abstract P4-08-15: Identification of target kinases whose inhibition enhances antitumor efficacy of sacituzumab-govitecan in metastatic HER2-negative breast cancer
Journal Articles

Abstract OT2-06-01: Breast Cancer Cohort of the Comprehensive Outcomes for After Cancer Health (COACH) Study: Study Protocol

Robin M. Lally, Rachael L. Schmidt, Gisele Tlusty, Elizabeth K. Arthur, Laura K. Flora, Jessica L. Krok-Schoen, Jessica T. Jones, Meagan Whisenant, Abbey Kaler, Debu Tripathy, Leorey Saligan, Marilyn Hammer, Austin Barr, Lindsey Jackson, Jennifer Loftis, Kelly J. Brassil
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT2-06-01.
https://doi.org/10.1158/1538-7445.SABCS22-OT2-06-01
Published: 01 March 2023
View article titled, Abstract OT2-06-01: Breast Cancer Cohort of the Comprehensive Outcomes for After Cancer Health (COACH) Study: Study Protocol
Journal Articles

Abstract P3-02-04: Phase II study of Pembrolizumab Maintenance treatment in patients with HER2-negative inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) after response to chemotherapy

Toshiaki Iwase, Angela Alexander, Vivian Chiv, Megumi Kai, Kumiko Kida, Charla Parker, Angela N. Marx, Evan Cohen, Hui Gao, James Reuben, Xiaoping Wang, Savitri Krishnamurthy, Diane Liu, Yu Shen, David Ramirez, Debu Tripathy, Daniel Booser, Clinton Yam, Vicente Valero, Bora Lim, Naoto T. Ueno, Jie S. Willey
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-02-04.
https://doi.org/10.1158/1538-7445.SABCS22-P3-02-04
Published: 01 March 2023
View article titled, Abstract P3-02-04: Phase II study of Pembrolizumab Maintenance treatment in patients with HER2-negative inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) after response to chemotherapy
Journal Articles

Abstract PD18-09: ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1

Sara Hurvitz, Kevin Kalinsky, Vinod Ganju, Kashif Ali, Laila Agrawal, William Gradishar, George Sledge, Anu Thummala, Arlene Chan, Sophia Frentzas, Joo Hyuk Sohn, Kyong-Hwa Park, Keon Uk Park, Catherine Shannon, Joshua Drago, Sara Tolaney, Hope Rugo, Michael F. Press, Alex Alika, Dong Xu, Janice Lu, Debu Tripathy
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD18-09.
https://doi.org/10.1158/1538-7445.SABCS22-PD18-09
Published: 01 March 2023
View article titled, Abstract PD18-09: ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1
Journal Articles

Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 trials

Aditya Bardia, Faye Su, Nadia Solovieff, Fabrice Andre, Carlos Arteaga, Patrick Neven, Yoon-Sim Yap, Yen-Shen Lu, Stephen K. Chia, Dennis Slamon, Seock-Ah Im, Arunava Chakravartty, Agnes Lteif, Tetiana Taran, Debu Tripathy
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD17-08.
https://doi.org/10.1158/1538-7445.SABCS22-PD17-08
Published: 01 March 2023
View article titled, Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 trials
Journal Articles

Abstract P5-02-30: Histology-based survival outcomes in HR+/HER2- metastatic breast cancer treated with targeted therapies plus endocrine therapy based on HER2 expression

Jason Mouabbi, Akshara Singareeka Raghavendra, Roland Bassett, Amy Hassan, Debu Tripathy, Rachel M. Layman
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-02-30.
https://doi.org/10.1158/1538-7445.SABCS22-P5-02-30
Published: 01 March 2023
View article titled, Abstract P5-02-30: Histology-based survival outcomes in HR+/HER2- metastatic breast cancer treated with targeted therapies plus endocrine therapy based on HER2 expression
Journal Articles

Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status

Irene Kang, Jamie K. Forschmiedt, Michelle M. Loch, William E. Barlow, Danika L. Lew, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Priya Rastogi, Anne F. Schott, Steven Shak, Priyanka Sharma, Jieling Miao, Debu Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi, Kevin Kalinsky, N. Lynn Henry
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): GS1-04.
https://doi.org/10.1158/1538-7445.SABCS22-GS1-04
Published: 01 March 2023
View article titled, Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status
Journal Articles

Abstract P4-08-01: Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer

Xuemei Xie, Marwa Manai, Jon A. Fuson, Troy Pearson, Dileep R. Rampa, Debu Tripathy, Jangsoon Lee, Naoto T. Ueno
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P4-08-01.
https://doi.org/10.1158/1538-7445.SABCS22-P4-08-01
Published: 01 March 2023
View article titled, Abstract P4-08-01: Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer
Journal Articles

Abstract P6-05-45: Providing Educational Resources during the Pandemic for Advanced Breast Cancer Patients

Ginny T. Kirklin, Abbey Kaler, Debu Tripathy
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P6-05-45.
https://doi.org/10.1158/1538-7445.SABCS22-P6-05-45
Published: 01 March 2023
View article titled, Abstract P6-05-45: Providing Educational Resources during the Pandemic for Advanced Breast Cancer Patients
Journal Articles

Abstract P5-02-22: Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib: Biomarker Results from POLARIS

Debu Tripathy, Joanne L. Blum, Shibing Deng, Steven L. McCune, Kamal Patel, Yao Wang, Shailendra Lakhanpal, Meghan S. Karuturi, Zhe Zhang, Chetan Deshpande, Monica Z. Montelongo, Eric Gauthier, Yuan Liu, Gabrielle B. Rocque, Aditya Bardia
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-02-22.
https://doi.org/10.1158/1538-7445.SABCS22-P5-02-22
Published: 01 March 2023
View article titled, Abstract P5-02-22: Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib: Biomarker Results from POLARIS
Journal Articles

Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

Fabrice Andre, Nadia Solovieff, Faye Su, Aditya Bardia, Patrick Neven, Yoon-Sim Yap, Debu Tripathy, Yen-Shen Lu, Dennis Slamon, Stephen K. Chia, Mukta Joshi, Arunava Chakravartty, Agnes Lteif, Tetiana Taran, Carlos Arteaga
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-02-14.
https://doi.org/10.1158/1538-7445.SABCS22-P5-02-14
Published: 01 March 2023
View article titled, Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
Journal Articles

Abstract HER2-04: HER2-04 Prevalence of HER2-low among Metastatic Breast Cancer Patients and Their Outcomes Compared to HER2 IHC 0

Akshara Singareeka Raghavendra, Diane Liu, Jason Mouabbi, Debu Tripathy
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): HER2-04.
https://doi.org/10.1158/1538-7445.SABCS22-HER2-04
Published: 01 March 2023
View article titled, Abstract HER2-04: HER2-04 Prevalence of HER2-low among Metastatic Breast Cancer Patients and Their Outcomes Compared to HER2 IHC 0
Journal Articles

Abstract P4-02-26: Quantitative estrogen receptor expression affects pathologic complete response to neoadjuvant chemotherapy in patients with early-stage breast cancer with low expression of HER2

Toshiaki Iwase, Takeo Fujii, Clinton Yam, Wenli Dong, Yu Shen, Debu Tripathy, Naoto T. Ueno
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P4-02-26.
https://doi.org/10.1158/1538-7445.SABCS22-P4-02-26
Published: 01 March 2023
View article titled, Abstract P4-02-26: Quantitative estrogen receptor expression affects pathologic complete response to neoadjuvant chemotherapy in patients with early-stage breast cancer with low expression of HER2
Journal Articles

Abstract P3-05-38: Biology and clinical course of lobular cancer in breast cancer (BC)

Akshara Singareeka Raghavendra, Roland Bassett, Jason Mouabbi, Rachel M. Layman, Debu Tripathy
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-05-38.
https://doi.org/10.1158/1538-7445.SABCS22-P3-05-38
Published: 01 March 2023
View article titled, Abstract P3-05-38: Biology and clinical course of lobular cancer in breast cancer (BC)
Journal Articles

Abstract P3-01-03: Characterization of neutropenia in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS

Debu Tripathy, Joanne L. Blum, Bethany Sleckman, Kamal Patel, Ibrahim Nakhoul, Eric Gauthier, Monica Z. Montelongo, Zhe Zhang, Yao Wang, Gabrielle B. Rocque
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-01-03.
https://doi.org/10.1158/1538-7445.SABCS22-P3-01-03
Published: 01 March 2023
View article titled, Abstract P3-01-03: Characterization of neutropenia in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS
Journal Articles

Abstract P6-10-08: Evaluation of potent novel second-generation MELK-selective inhibitor in aggressive breast cancers

Mohd Mughees, Moises Tacam, Alex Tan, Hector Gonzalez, Emilly S. Villodre, Bisrat Debeb, Debu Tripathy, Geoffrey Bartholomeusz, Juhyeon Lee, Kevin Dalby, Chandra Bartholomeusz
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P6-10-08.
https://doi.org/10.1158/1538-7445.SABCS22-P6-10-08
Published: 01 March 2023
View article titled, Abstract P6-10-08: Evaluation of potent novel second-generation MELK-selective inhibitor in aggressive breast cancers